Compare Stocks → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNTBNASDAQ:KMDANASDAQ:PRDSNASDAQ:RLYBNASDAQ:STTK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.37-1.4%$1.45$0.53▼$2.84$75.45M-0.61145,551 shs41,055 shsKMDAKamada$5.18+1.8%$5.72$4.08▼$6.53$292.55M1.0419,430 shs10,902 shsPRDSPardes Biosciences$2.16$2.16$0.75▼$3.93$133.95M0.42359,530 shs400 shsRLYBRallybio$1.58-9.2%$1.81$1.23▼$9.14$65.79M-1.644.57 million shs279,650 shsSTTKShattuck Labs$9.90+4.3%$9.21$1.33▼$11.11$450.54M2.11268,866 shs234,436 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-1.44%-11.61%+7.87%+5.38%+32.88%KMDAKamada+1.57%+1.97%-9.60%-8.16%+15.63%PRDSPardes Biosciences0.00%0.00%0.00%0.00%+16.76%RLYBRallybio-9.20%-10.23%+5.33%+12.86%-68.65%STTKShattuck Labs+4.32%-1.20%+8.32%-0.90%+241.38%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma3.0441 of 5 stars3.53.00.00.03.82.50.6KMDAKamada4.0262 of 5 stars3.55.00.00.01.81.73.1PRDSPardes BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ARLYBRallybio2.2186 of 5 stars3.41.00.00.03.11.71.3STTKShattuck Labs1.1388 of 5 stars3.52.00.00.01.11.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma3.00Buy$6.50374.45% UpsideKMDAKamada3.00Buy$11.00112.36% UpsidePRDSPardes Biosciences2.00HoldN/AN/ARLYBRallybio2.83Moderate Buy$12.20672.15% UpsideSTTKShattuck Labs3.00Buy$20.00102.02% UpsideCurrent Analyst RatingsLatest STTK, PRDS, KMDA, RLYB, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024RLYBRallybioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/17/2024CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.004/11/2024RLYBRallybioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $11.004/9/2024STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/13/2024RLYBRallybioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/13/2024RLYBRallybioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/4/2024CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.003/1/2024STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/1/2024STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/13/2024STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect BiopharmaN/AN/AN/AN/A$1.83 per shareN/AKMDAKamada$142.52M2.09$0.43 per share11.94$4.25 per share1.22PRDSPardes BiosciencesN/AN/AN/AN/A$2.51 per shareN/ARLYBRallybioN/AN/AN/AN/A$2.81 per shareN/ASTTKShattuck Labs$1.66M283.10N/AN/A$3.41 per share2.90Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AKMDAKamada$8.28M$0.1534.5312.63N/A5.81%5.66%3.57%5/22/2024 (Estimated)PRDSPardes Biosciences-$96.63M-$1.29N/AN/AN/AN/A-43.36%-40.71%N/ARLYBRallybio-$74.56M-$1.84N/AN/AN/AN/A-56.90%-53.38%5/14/2024 (Estimated)STTKShattuck Labs-$87.30M-$2.05N/AN/AN/A-5,268.44%-63.08%-56.05%5/14/2024 (Estimated)Latest STTK, PRDS, KMDA, RLYB, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023RLYBRallybio-$0.44-$0.50-$0.06-$0.50N/AN/A3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 million2/29/2024Q4 2023STTKShattuck Labs-$0.51-$0.41+$0.10-$0.41$0.50 million$0.71 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/APRDSPardes BiosciencesN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect BiopharmaN/A4.994.99KMDAKamadaN/A3.431.64PRDSPardes BiosciencesN/A81.7281.72RLYBRallybioN/A12.3912.39STTKShattuck LabsN/A12.5112.51OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%KMDAKamada20.38%PRDSPardes Biosciences91.89%RLYBRallybio90.34%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%KMDAKamada36.10%PRDSPardes Biosciences40.80%RLYBRallybio7.40%STTKShattuck Labs9.89%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma10055.07 million42.63 millionOptionableKMDAKamada37857.47 million36.73 millionOptionablePRDSPardes Biosciences5762.01 million36.71 millionNot OptionableRLYBRallybio4337.81 million35.01 millionNot OptionableSTTKShattuck Labs7547.47 million42.78 millionOptionableSTTK, PRDS, KMDA, RLYB, and CNTB HeadlinesSourceHeadlineShattuck Labs (NASDAQ:STTK) and Puma Biotechnology (NASDAQ:PBYI) Head-To-Head Analysisamericanbankingnews.com - April 22 at 1:26 AMSTTK May 2024 7.500 callca.finance.yahoo.com - April 20 at 7:25 AMOwning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),finance.yahoo.com - April 18 at 1:06 PMHead-To-Head Comparison: Shattuck Labs (NASDAQ:STTK) and Ovid Therapeutics (NASDAQ:OVID)americanbankingnews.com - April 18 at 1:16 AMFY2025 EPS Estimates for Shattuck Labs, Inc. Cut by Analyst (NASDAQ:STTK)americanbankingnews.com - April 15 at 1:50 AMShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - April 9 at 4:05 PMStrong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and Leadershipmarkets.businessinsider.com - April 9 at 3:39 PMShattuck Labs (NASDAQ:STTK) Stock Rating Reaffirmed by Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMShattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 1 at 7:00 AMSTTK Apr 2024 17.500 callfinance.yahoo.com - March 16 at 9:05 PMSTTK Apr 2024 7.500 putfinance.yahoo.com - March 16 at 9:05 PMInsider Selling: Shattuck Labs, Inc. (NASDAQ:STTK) Insider Sells 16,004 Shares of Stockinsidertrades.com - March 11 at 7:00 AMShattuck Labs Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 6 at 7:15 PMShattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.globenewswire.com - March 4 at 7:00 AMBuy Rating Justified: Shattuck Labs’ Breakthrough in Cancer Immunotherapy and Strong Financialsmarkets.businessinsider.com - March 2 at 3:44 PMShattuck Labs (STTK) Receives a Buy from TD Cowenmarkets.businessinsider.com - March 1 at 1:13 AMShattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - February 29 at 4:05 PMShattuck Labs Announces Participation in Upcoming March Conferencesglobenewswire.com - February 26 at 7:00 AMSTTK Mar 2024 17.500 callfinance.yahoo.com - February 23 at 8:33 AMShattuck Labs Stock (NASDAQ:STTK) Dividends: History, Yield and Datesbenzinga.com - February 21 at 11:19 PMSTTK Mar 2024 5.000 putfinance.yahoo.com - February 17 at 6:48 PMSTTK Mar 2024 10.000 callfinance.yahoo.com - February 17 at 8:47 AMSTTK Mar 2024 10.000 putfinance.yahoo.com - February 17 at 8:47 AMBuy Rating Affirmed: Shattuck Labs’ Promising Partnerships and Clinical Advancementsmarkets.businessinsider.com - February 14 at 3:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsConnect BiopharmaNASDAQ:CNTBConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Pardes BiosciencesNASDAQ:PRDSPardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.RallybioNASDAQ:RLYBRallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Shattuck LabsNASDAQ:STTKShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.